HIF prolyl hydroxylase inhibitors for anemia

Bibliography

• Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;20:5447-54
   Google Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian Y-M, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-7
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5
   PubMed Web of Science ®Google Scholar
• Lando D, Peet DJ, Whelan DA, Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002;295:858-61
   PubMed Web of Science ®Google Scholar
• Hewitson KS, McNeill LA, Riordan MV, Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002;277:26351-5
   PubMed Web of Science ®Google Scholar
• Lando D, Peet DJ, Gorman JJ, FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71
   PubMed Web of Science ®Google Scholar
• Ehrismann D, Flashman E, Genn DN, Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J 2007;401:227-34
   PubMed Web of Science ®Google Scholar
• Page EL, Chan DA, Giaccia AJ, Hypoxia-inducible factor-1alpha stabilization in non-hypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008;19:86-94
   PubMed Web of Science ®Google Scholar
• Selak MA, Armour SM, MacKenzie ED, Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Jung YJ, Mole DR, HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-53
   PubMed Web of Science ®Google Scholar
• Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007;117:862-5
   PubMed Web of Science ®Google Scholar
• Makino Y, Cao R, Svensson K, Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4
   PubMed Web of Science ®Google Scholar
• Makino Y, Kanopka A, Wilson WJ, Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002;277:32405-8
   PubMed Web of Science ®Google Scholar
• Ortiz-Barahona A, Villar D, Pescador N, Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 2010;38:2332-45
   PubMed Web of Science ®Google Scholar
• Gruber M, Hu CJ, Johnson RS, Acute postnatal ablation of Hif-2_ results in anemia. Proc Natl Acad Sci USA 2007;104:2301-6
   PubMed Web of Science ®Google Scholar
• Scortegagna M, Ding K, Zhang Q, HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005;105:3133-40
   PubMed Web of Science ®Google Scholar
• Paliege A, Rosenberger C, Bondke A, Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 2010;77:312-18
   PubMed Web of Science ®Google Scholar
• Furlow PW, Percy MJ, Sutherland S, Erythrocytosis-associated HIF-2_ mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem 2009;284:9050-8
   PubMed Web of Science ®Google Scholar
• Gale DP, Harten SK, Reid CD, Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2alpha mutation. Blood 2008;112:919-21
   PubMed Web of Science ®Google Scholar
• Martini M, Teofili L, Cenci T, A novel heterozygous HIF2alpha M535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 2008;93:1068-71
   PubMed Web of Science ®Google Scholar
• Percy MJ, Furlow PW, Lucas GS, A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008;358:162-8
   PubMed Web of Science ®Google Scholar
• van Wijk R, Sutherland S, Van Wesel AC, Erythrocytosis associated with a novel missense mutation in the HIF2A gene. Haematologica 2010;95(5):829-32
   PubMed Web of Science ®Google Scholar
• Bosch-Marce M, Okuyama H, Wesley JB, Effects of aging and hypoxia inducible factor 1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007;101:1310-18
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64
   PubMed Web of Science ®Google Scholar
• Forsythe JA, Jiang BH, Iyer NV, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13
   PubMed Web of Science ®Google Scholar
• Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol 2008;217:809-18
   PubMed Web of Science ®Google Scholar
• Fukuda R, Zhang H, Kim JW, HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007;129:111-22
   PubMed Web of Science ®Google Scholar
• Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85
   PubMed Web of Science ®Google Scholar
• Iyer NV, Kotch LE, Agani F, Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha. Genes Dev 1998;12:149-62
   PubMed Web of Science ®Google Scholar
• Seagroves TN, Ryan HE, Lu H, Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21:3436-44
   PubMed Web of Science ®Google Scholar
• Semenza GL, Jiang BH, Leung SW, Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia inducible factor 1. J Biol Chem 1996;271:32529-37
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Liu Q, Unger TL, Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010;116:3039-48
   PubMed Web of Science ®Google Scholar
• Shah YM, Matsubara T, Ito S, Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 2009;9:152-64
   PubMed Web of Science ®Google Scholar
• Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-32
   PubMed Web of Science ®Google Scholar
• Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997;272:20055-62
   PubMed Web of Science ®Google Scholar
• Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin gene. J Biol Chem 1999;274:24147-52
   PubMed Web of Science ®Google Scholar
• Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia: HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274:24142-6
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275:21048-54
   PubMed Web of Science ®Google Scholar
• Liu YL, Ang SO, Weigent DA, Regulation of ferrochelatase gene expression by hypoxia. Life Sci 2004;75:2035-43
   PubMed Web of Science ®Google Scholar
• Mastrogiannaki M, Matak P, Keith B, HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009;119:1159-66
   PubMed Web of Science ®Google Scholar
• McMahon S, Grondin F, McDonald PP, Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 2005;280:6561-9
   PubMed Web of Science ®Google Scholar
• Silvestri L, Pagani A, Camaschella C. Furin mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2007;109:4503-10
   PubMed Web of Science ®Google Scholar
• Lieb ME, Menzies K, Moschella MC, Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 2002;80:421-6
   PubMed Web of Science ®Google Scholar
• Berra E, Benizri E, Ginouves A, HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1a in normoxia. EMBO J 2003;22:4082-90
   PubMed Web of Science ®Google Scholar
• Appelhoff RJ, Tian YM, Raval RR, Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279:38458-65
   PubMed Web of Science ®Google Scholar
• Aragones J, Schneider M, Van Geyte K, Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008;40:170-80
   PubMed Web of Science ®Google Scholar
• Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007;116:774-81
   PubMed Web of Science ®Google Scholar
• Takeda K, Aguila HL, Parikh NS, Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008;111:3229-35
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Moslehi J, Bardeesy N, Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008;111:3236-44
   PubMed Web of Science ®Google Scholar
• Bishop T, Gallagher D, Pascual A, Abnormal sympathoadrenal development and systemic hypotension in PHD3 mice. Mol Cell Biol 2008;28:3386-400
   PubMed Web of Science ®Google Scholar
• Choudhury R, Hardy A, Schofield CJ. The human oxygen sensing machinery and its manipulation. Chem Soc Rev 2008;37:1308-19
   PubMed Web of Science ®Google Scholar
• Cockman ME, Webb JD, Kramer HB, Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Mol Cell Proteomics 2009;8:535-46
   PubMed Web of Science ®Google Scholar
• Coleman ML, McDonough MA, Hewitson KS, Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem 2007;282:24027-38
   PubMed Web of Science ®Google Scholar
• Zheng X, Linke S, Dias JM, Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci USA 2008;105:3368-73
   PubMed Web of Science ®Google Scholar
• Zhang N, Fu Z, Linke S, The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab 2010;11:364-78
   PubMed Web of Science ®Google Scholar
• Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564-70
   PubMed Web of Science ®Google Scholar
• Ang SO, Chen H, Hirota K, Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32(4):614-21
   PubMed Web of Science ®Google Scholar
• van Wijk R, Sutherland S, Van Weset ACW, Erythrocytosis associated with a novel missense mutation in the HIF2A gene. Haematologica 2010;95(5):829-32
   PubMed Web of Science ®Google Scholar
• Percy MJ, Zhao Q, Flores A, A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006;103(3):654-9
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA binding activity: Implications for models of hypoxia signal transduction. Blood 1993;82:3610-5
   PubMed Web of Science ®Google Scholar
• Heimpel H. Stimulation of hemopoiesis in aplastic anemia. Haematol Blood Transfus 1979;24:129-37
   PubMedGoogle Scholar
• Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:1412-5
   PubMed Web of Science ®Google Scholar
• McDonoguh MA, McNeill LA, Tilliet M, Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc 2005;127:7680-1
   PubMed Web of Science ®Google Scholar
• Schlemminger I, Mole DR, McNeill LA, Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases. Bioorg Med Chem Lett 2003;13:1451-4
   PubMed Web of Science ®Google Scholar
• Warshakoon NC, Wu S, Boyer A, A novel series of imidazo[1,2-a]pyridine derivates as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 2006;16:5598-601
   PubMed Web of Science ®Google Scholar
• Murray JK, Balan C, Allgeier AM, Dipeptidyl-quinolone derivatives inhibit hypoxia inducible factor-1alpha prolyl hydroxylases-1, -2, and –3 with altered selectivity. J Comb Chem 2011. [Epub ahead of print]
   Google Scholar
• Lienard BM, Conejo-Garcia A, Stolze I, Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases. Chem Commun 2008;47:6393-5
   PubMedGoogle Scholar
• Rajagopalan S, Olin J, Deitcher S, Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007;115(10):1234-43
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316(2):73-8
   PubMed Web of Science ®Google Scholar
• Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1-4
   PubMed Web of Science ®Google Scholar
• Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300(6724):573-8
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, ; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, ; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, ; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74(6):791-8
   PubMed Web of Science ®Google Scholar
• Valeri CR, Cassidy G, Pivacek LE, Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001;41:977-83
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003;29:451-8
   PubMed Web of Science ®Google Scholar
• Stohlawetz PJ, Dzirlo L, Hergovich N, Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-89
   PubMed Web of Science ®Google Scholar
• Kirkeby A, Torup L, Bochsen L, High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 2008;99:720-8
   PubMed Web of Science ®Google Scholar
• Patel TV, Mittal BV, Keithi-Reddy SR, Endothelial activation markers in anemic nondialysis chronic kidney disease patients. Nephron Clin Pract 2008;110:c244-50
   PubMed Web of Science ®Google Scholar
• Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010;29:86-92
   PubMed Web of Science ®Google Scholar
• Kanbay M, Perazzella MA, Kasapoglu B, Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010;29:1-12
   PubMed Web of Science ®Google Scholar
• Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology 2007;12:321-30
   PubMed Web of Science ®Google Scholar
• Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2009. [Epub ahead of print]
   Google Scholar
• Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008;40:132-8
   PubMed Web of Science ®Google Scholar
• Mole DR. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 2010;12(4):445-58
   PubMed Web of Science ®Google Scholar
• Klaus S, Langsetmo I, Neff T, Beneficial pharmacodynamic effects resulting from “complete erythropoiesis” induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592. J Am Soc Nephrol 2008;19:524A
   Google Scholar
• Besarab A, Hulter HN, Klaus S, FG-4592, a novel oral HIF prolyl hydroxylase inhibitor (HIF-PHI), elevates hemoglobin in anemic stage 3-4 CKD patients. J Am Soc Nephrol 2010;21:95A
   Google Scholar
• Bernhardt WM, Wiesener MS, Scigalla P, Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21:2151-6
   PubMed Web of Science ®Google Scholar
• Provenzano R, Fadda G, Bernardo M, FG-2216, A novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD. Am J Kidney Dis 2008;51(4):B80
   PubMedGoogle Scholar
• Frohna PA, Milwee S, Pinkett J, Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in subjects with CKD anemia. J Am Soc Nephrol 2007;18:515A
   PubMedGoogle Scholar
• Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007;64(16):2170-80
   PubMed Web of Science ®Google Scholar
• Chan DA, Giaccia AJ. PHD2 in tumour angiogenesis. Br J Cancer 2010;103(1):1-5
   PubMed Web of Science ®Google Scholar
• Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15(4):678-85
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 2010;9(9):1722-8
   PubMed Web of Science ®Google Scholar
• Seeley TW, Sternlicht MD, Stephenson R, HIF prolyl hydroxylase inhibitors increase erythropoiesis without promotion of tumor progression in the presence or absence of concomitant chemotherapy [abstract 364]. Keystone Symposium Molecular, Cellular, Physiological and Pathogenic Responses of Hypoxia; 2008
   Google Scholar
• Seeley TW, Langsetmo I, Stephenson R, FG2216: tumor progression studies and correction of anemia of chronic disease in xenograft models. J Am Soc Nephrol 2005;16:481A
   Google Scholar
• Zhang Q, Gu J, Li L, Control of Cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009;16:1-12
   PubMedGoogle Scholar
• Natarajan R, Salloum FN, Fisher BJ, Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol 2008;51:178-87
   PubMed Web of Science ®Google Scholar
• Hyvarinen J, Hassinen IE, Sormunen R, Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 2010;285:13646-57
   PubMed Web of Science ®Google Scholar
• Bao W, Qin P, Needle S, Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 2010;56(2):147-55
   PubMed Web of Science ®Google Scholar
• Kilian EG, Sadoni S, Vicol C, Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting – a multicenter phase I and safety study. Circ J 2010;74(5):916-24
   PubMed Web of Science ®Google Scholar
• Harten SK, Ashcroft M, Maxwell PH. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 2010;12(4):459-80
   PubMed Web of Science ®Google Scholar
• Niatsetskaya Z, Basso M, Speer RE, HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 2010;12(4):435-43
   PubMed Web of Science ®Google Scholar
• Weidemann A, Bernhardt WM, Klanke B, HIF activation protects from acute kidney injury. J Am Soc Nephrol 2008;19:486-94
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Campean V, Kany S, Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 2006;17(7):1970-8
   PubMed Web of Science ®Google Scholar
• Amador A, Grande L, Marti J, Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. Am J Transplant 2007;7(9):2180-9
   PubMed Web of Science ®Google Scholar
• Cantley J, Selman C, Shukla D, Deletion of the von hippel-Linday gene in pancreatic beta cells impairs glucose homeostasis in mice. J Clin Invest 2009;119:125-35
   PubMed Web of Science ®Google Scholar
• Cheng K, Ho K, Stokes R, Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest 2010;120:2171-83
   Google Scholar
• Shimoda LA, Semenza GL. HIF and the lung – role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 2011;183:152-6
   PubMed Web of Science ®Google Scholar
• Farha S, Asosingh K, Xu W, Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011. [Epub ahead of print]
   Google Scholar
• Yu AY, Shimoda LA, Iyer NV, Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999;103:691-6
   PubMed Web of Science ®Google Scholar
• Brusselmans K, Compernolle V, Tjwa M, Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 2003;111:1519-27
   PubMed Web of Science ®Google Scholar